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Abstract
Background: Erythropoietin is a growth factor commonly used to manage anemia in patients with chronic kidney disease. A
significant clinical challenge is relative resistance to erythropoietin, which leads to use of successively higher erythropoietin
doses, failure to achieve target hemoglobin levels, and increased risk of adverse outcomes. Erythropoietin acts through the
erythropoietin receptor (EpoR) present in erythroblasts. Alternative mRNA splicing produces a soluble form of EpoR (sEpoR)
found in human blood, however its role in anemia is not known.
Methods and Findings: Using archived serum samples obtained from subjects with end stage kidney disease we show that
sEpoR is detectable as a 27kDa protein in the serum of dialysis patients, and that higher serum sEpoR levels correlate with
increased erythropoietin requirements. Soluble EpoR inhibits erythropoietin mediated signal transducer and activator of
transcription 5 (Stat5) phosphorylation in cell lines expressing EpoR. Importantly, we demonstrate that serum from patients
with elevated sEpoR levels blocks this phosphorylation in ex vivo studies. Finally, we show that sEpoR is increased in the
supernatant of a human erythroleukaemia cell line when stimulated by inflammatory mediators such as interleukin-6 and
tumor necrosis factor alpha implying a link between inflammation and erythropoietin resistance.
Conclusions: These observations suggest that sEpoR levels may contribute to erythropoietin resistance in end stage renal
disease, and that sEpoR production may be mediated by pro-inflammatory cytokines.
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Introduction
Management of anemia with erythropoietin in patients with
renal failure on dialysis has significantly changed clinical practice
in nephrology. The widespread clinical use of recombinant
erythropoietin has reduced the requirement for blood transfusions
and is associated with improved left ventricular hypertrophy [1] as
well as quality of life outcomes in dialysis patients [2–4]. Recent
clinical studies, however, have suggested an excess of cardiovas-
cular events in patients requiring elevated doses of erythropoietin
[5–7] and a trend toward excess mortality in dialysis patients with
higher hemoglobin targets [8]. It is not clear if this excess risk is
related to erythropoietin dose or an absolute rise in hemoglobin
concentration. As a result there is significant debate about optimal
erythropoietin dose and hemoglobin targets. Nevertheless, eryth-
ropoietin therapy still remains a cornerstone in the management of
anemia in chronic dialysis patients.
Erythropoietin is protein hormone produced by the kidney in
response to hypoxia. Erythropoietin binds the membrane bound
erythropoietin receptor (EpoR) located on erythroblasts in the
bone marrow. Following receptor binding, an intracellular
signaling cascade leads to the transcription of anti-apoptotic
genes. This results in production of new red blood cells and
improvement in anemia. While most patients respond well to
erythropoietin, a subset of patients are considered resistant to
erythropoietin, requiring 25–100% higher doses than the average
patient to maintain acceptable hemoglobin levels [9–11]. This lack
of response termed ‘‘Erythropoietin Resistance’’ or ‘‘Erythropoi-
etin Hyporesponsiveness’’ is multifactorial but may be related to
iron stores (both absolute and effective), renal osteodystrophy, and
inflammation [9–11]. Generally patients who receive in excess of
400 IU/kg per week of erythropoietin and fail to achieve target
hemoglobin are considered resistant although there is clearly a
spectrum of erythropoietin sensitivity [9]. It remains clinically
challenging to accurately predict which patients will be resistant to
erythropoietin prior to initiating erythropoietin therapy. Chronic
inflammation seems to play a role in some patients and there is
evidence that inflammatory cytokines may down regulate the bone
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may be functional iron deficiency related to inadequate delivery of
iron to the erythroid marrow in the face of adequate iron sores in
the reticuloendothelial system [12]. Iron delivery may be inhibited
by inflammatory cytokines and hormones such as hepcidin which
may play a role in renal anemia [13–15]. In addition, markers of
erythropoiesis such as the soluble transferrin receptor (sTfR) may
be useful in determining appropriate iron management strategies
[16–19].
EpoR is a membrane-bound receptor present in erythroblasts
and is a member of the cytokine superfamily of type 1
transmembrane proteins [20,21]. Erythropoietin binding results
in phosphorylation of intracellular messengers such as Stat-5 that
bind tyrosine residues, become phosphorylated and translocate to
the nucleus to initiate gene transcription [22]. Other intracellular
signaling cascades may be activated as well including phospho-
inositide 3-kinase, IkappaB kinase, and heat shock protein 70 [22],
leading to transcription of anti-apoptotic factors [22]. Importantly,
alternative mRNA splicing produces a soluble form of EpoR
(sEpoR) that is present in human blood [23–25]. Soluble EpoR
consists of the extracellular domain only and has a reported
molecular weight of between 27 and 34 kDa with differences
presumed related to glycosylation, although sEpoR protein has not
yet been purified from serum or sequenced [23,25–27]. It is also
possible that there is more than one form of circulating sEpoR [28]
as more than one splice variant have been identified [29]. The
function of sEpoR is unknown, but levels are thought to correlate
with the amount of erythropoiesis, raising the possibility of a
physiologic role for this soluble receptor [25,30]. Soluble EpoR
has been identified in human serum and plasma as well as a
number of tissues including brain, liver, spleen, kidney, heart and
bone marrow [30,31]. It has also been identified as a secreted
product from several cancer cell lines [29]. It is well known that
soluble receptors often play an important role in cytokine signaling
by stabilizing their ligand, changing concentrations of active ligand
or by altering the interaction between endogenous cytokine and
membrane bound ligand [32,33]. Although it has been shown that
secreted sEpoR is able to bind erythropoietin, the role of
circulating sEpoR in humans remains largely unknown [25,30,34].
We hypothesized that circulating sEpoR competes with
erythropoietin for receptor binding and that elevated levels of
sEpoR at initiation of hemodialysis portend increased erythropoi-
etin dose requirements needed to sustain target hemoglobin levels.
Furthermore we hypothesized that sEpoR production may be
mediated by inflammatory cytokines present in the uremic milieu.
Materials and Methods
Immunoprecipitation
Human serum samples from ESRD subjects (approximately
1 ml) were mixed in a 1:1 ratio with IP lysis buffer (150 mM NaCl,
10 mM Tris pH 7.5, 1 mM EDTA, 50 nM NaF, 1%Triton X,
0.5% NP40, Na Orthovanadate 200 mM, PMSF 10 mg/ml,
protease Inhibitor and phosphatase inhibitor at 4uC. Primary
antibody directed against EpoR (R&D Systems, AF-322-PB goat
anti-human polyclonal or R&D Systems, MAB307 mouse anti-
human monoclonal (approximately 0.5 mg/reaction) was added to
each tube and incubated over night at 4uC.followed by
precipitation with Protein G coated magnetic beads, then pelleted
and supernatant discarded. Beads were washed three times with
lysis buffer. Bound proteins were eluted with 2X loading buffer
(Laemmli’s SDS–sample buffer 4x reducing, Boston BioProducts
No. BP-110R) according to manufacturer’s recommendations.
The supernatant was retained and the beads discarded. Equal
amounts of eluted proteins were separated on an acrylamide 4–
12% gradient gel. Protein was transferred to PDVF using a semi-
dry transfer and western blotting performed using either of the two
EpoR antibodies at concentrations of 1/1,000 (R&D Systems,
MAB307 mouse anti-human monoclonal or R&D Systems, AF-
322-PB goat anti-human polyclonal).
Protein Sequencing/Mass Spectrometry
Immunoprecipitation was performed as described above with
the exception that 30 ml of pooled serum from uremic subjects
were used. Denaturing acrylamide gels were stained with 0.1%
Coomassie Brilliant Blue. A band of appropriate size and a section
of gel for negative control were cut out and rinsed in 1%
acetonitrile. Gel fragments were subject to trypsin digest and mass
spectrometry at the Beth Israel Deaconess proteomics core
laboratory. Briefly, the samples were treated with trypsin (1:100)
and resuspended in 1% trifluoroacetic acid and injected it into a
CapLC (Waters) high performance liquid chromatography
instrument. The peptides were separated using a 75 mm Nano
Series column (LC Packings) and analyzed them using a Qstar XL
MS/MS system. The peptides were searched using the Mascot
search engine (Matrix Science) against the human protein
database NCBInr.
sEpoR ELISA
ELISA testing of serum samples and cell culture supernatants
was performed using an Erythropoietin Receptor DuoSet ELISA
(DY307, R&D Systems, Minneapolis, MN). On the day of the
ELISA assay, frozen serum or cell culture supernatant samples
were thawed at room temperature and 100 ml (100%) serum was
added to each well. A standard curve was generated using serial
dilutions of recombinant sEpoR (R&D Systems 307-ER/CF) at
concentrations ranging from 4 ng/ml to 62.5 pg/ml in Reagent
Diluent (1% BSA/Phosphate Buffered Saline, R&D Systems
DY995). All reactions were carried out at room temperature.
Plates were coated overnight with primary mouse anti-human
EpoR antibody in PBS 1 mg/mL (100 ml/well). On the day of the
assay each well was washed three times with wash buffer (0.05%
Tween 20/Phosphate Buffered Saline, R&D Systems WA126)
400 ml/well using a Columbus Pro washer (Tecan, Inc). Reagent
Diluent 300 ml/well was added and plates incubated for 1 hour.
Plates were then washed three times with wash buffer and 100 ml
standard or sample was added to each well. Plates were incubated
for 4 hours on a table top shaker and washed three times with
400 ml/well Wash Buffer. Secondary biotinylated mouse anti-
human EpoR antibody 500 ng/ml (100 ml/well) was added and
plates were incubated for 2 hours on a table top shaker. Plates
were washed again with Wash Buffer three times and Streptavidin
conjugated to Horseradish-Peroxidase (100 ml/well) was added for
20 minutes. Plates were washed three times in wash buffer and
color reagent containing H202 and tetramethylbenzidine (100 ml/
well) was added (R&D Systems DY993). Plates were incubated for
20 minutes and Stop Solution 2N H2S04 50 ml (R&D Systems
DY994) was added to each well. Optical density was measured
using a Microplate Reader (BioRad, Model 660). Optical density
at 550 nm was subtracted from optical density at 450 nm and
serum concentrations were determined using a standard curve
generated by a quadratic plot of the standard sample concentra-
tions versus the measured optical density. We ran the assay in
duplicate for all samples with the exception of 18 serum samples
which were measured only once as we were limited by sample
volume. The operator was blinded to the clinical data.
The antibodies used in the R&D Systems DuoSet ELISA have
proprietary epitopes that target the extracellular region of the
Erythropoietin and Anemia
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alternative recombinant sEpoRs (Sigma-Aldrich E0643 and R&D
Systems 963-ER) in addition to the sEpoR (R&D Systems 307-
ER/CF) used to generate the standard curve. We calculated intra
and inter-assay coefficients of variance using 3 serum samples run
in triplicate on three separate plates. The mean intra assay
coefficient of variance for the three samples was 4.71% range
(1.10% to 9.49%) and the mean inter assay coefficient of variance
was 4.74% range (1.20% to 9.27%). We also tested for
erythropoietin interference by spiking both serum and control
wells with recombinant erythropoietin up to 10,000 mU/ml and
observed no significant alteration in EpoR measurements
suggesting the assay measures total sEpoR rather than free sEpoR.
BaF3/EpoR Stat-5 Signaling Assay
BaF3/EpoR cells stably expressing the EpoR receptor were
obtained from Dr. Laurie Feldman, Beth Israel Deaconess Medical
Center [35,36]. Cells were plated at 500,000 cells per well in a 24
well dish and grown overnight in RPMI with 1% FCS. Media was
replaced with serum free media and incubated for 12 hours.
Vehicle, recombinant erythropoietin (Amgen), human serum, and
recombinant receptor (R&D Systems) was added to wells to a total
volumeof500 ml(50 ml serumper well)with erythropoietin 50 mU/
ml and recombinant receptor. Cells were incubated for 10 minutes
at 37u, and immediately lysed in RIPA buffer with protease
inhibitors and samples frozen at 280uC for further analysis by
western blots using phospho-Stat-5 and Stat-5 antibodies (Stat-5
antibody (No. 9363), phospho-Stat-5, Thyr694, antibody
(No. 9351) both from Cell Signaling Technology, Danvers MA.
Statistical Considerations for In Vitro Data
Standard statistical analysis was performed on all data. Individual
values were collated as means +/2 S.E.M. Comparisons between
multiple groups were by a two way ANOVA test followed by a
Mann-Whitney nonparametric test or a paired t test when
appropriate. Statistical significance was considered if p ,0.05.
Human Subjects
In order to test if sEpoR levels at the initiation of chronic
hemodialysis are correlated with subsequent erythropoietin
requirements, we selected consecutive chronic hemodialysis
(CHD) patients from the Accelerated Mortality on Renal
Replacement (ArMORR) cohort study which has been described
in detail [37–41]. This study was approved by the Institutional
Review Board of the Massachusetts General Hospital and
informed consent was waived by the Institutional Review board
as only archived samples were used in this study. ArMORR
includes 10,044 subjects who initiated CHD at any one of the
1056 U.S. dialysis centers operated by Fresenius Medical Care
North America (Waltham, MA) between 2004 and 2005. All the
subjects underwent 1 year follow-up except for those who died
(15%), underwent kidney transplant (3%), recovered renal function
(4%), or transitioned to a dialysis unit outside the Fresenius
Medical Care North America system before completing 1 year of
hemodialysis treatment (12%).
Within this cohort we targeted 500–1000 consecutive patients
with adequate baseline blood samples and who survived at least 6
months so as to examine erythropoietin requirements during this
time period. This sample size was chosen based on our previous
studies examining baseline levels of other parameters and
subsequent outcomes [37,39], and because no prior human data
were available to provide us with an estimate of effect size and
appropriate sample size to achieve adequate power. Of these, 697
subjects representing over 400 CHD units in the U.S. had
adequate remnant volumes of baseline samples with complete
erythropoietin dosing information (amount of erythropoietin
administered at each dialysis session). Specifically, each subject
had a blood sample collected within 14 days of initiating CHD and
each subject was new to CHD. No subject had ever undergone
CHD or peritoneal dialysis in the past, and no subject had ever
undergone a renal transplantation prior to enrollment or
recovered renal function during the study period. We measured
sEpoR levels by ELISA assay and the distribution plot suggested
that approximately 5% of ESRD subjects had high circulating
levels of EpoR (.2 standard deviations from the mean). We
therefore divided the 697 patients into two groups based on sEpoR
levels at CHD start. The High sEpoR group had sEpoR levels
$800 pg/ml (n=36), and the Low sEpoR group (n=661)
included the remainder.
Statistical Considerations for Clinical Study
Categorical and continuous variables were examined using
standard univariate tests for comparison. Longitudinal analysis
was used to test the group (sEpoR Low vs. High) differences over
time. Cumulative erythropoietin dose was categorized as follows:
mean weekly dose administered between days 0 and 14 (14d) after
initiating CHD; mean weekly dose administered between days 14
and 90 (90d); and mean weekly dose administered between days
90 and 180 (180d). Mean hemoglobin levels were categorized in a
similar fashion. We performed repeated measures ANOVA to
examine within and between sEpoR group comparisons. The
interaction between time and sEpoR group status was tested to
determine whether the relationship with erythropoietin require-
ments and hemoglobin levels differed between groups over time.
Logistic and linear regression analyses were used to adjust for
potential confounders. All analyses were performed using SAS
version 9.1 for Windows (SAS Institute Inc., Cary, NC, USA).
Two-sided P values ,0.05 were considered statistically significant.
Cell Culture, Stimulation of K562 Cells and Assay of sEpoR
in Supernatants
K562 cells (ATCC, Virginia, CCL-243) were maintained in
IMDM media +10% FCS were plated at 500,000 cells per well in a
12 well plate without serum. At time zero cells were exposed to
vehicle, phorbol ester 500 nM and 1000 nM,TNF-a 50 ng/ml, IL-
6 10 ng/ml, and IL-8 10 ng/ml, in triplicate for 48 hours. At the
end of 48 hours cells were pelleted at 4uC. The supernatant was
collected and stored at 280uC. EpoR ELISA was performed on the
supernatants as described above. Protein assay was performed as
follows using BCA protein assay (Pierce, Thermo Fisher Scientific,
Rockford IL) according to manufacturer’s standard protocol.
IL-6 Levels
Serum IL-6 was measured using a commercially available
ELISA kit (Catalog # DY6050, R&D Systems, MN) and
manufacturer’s instructions were followed. All 32 subjects with
high sEpoR (.800 pg/ml) who had remaining serum available
and an equal number of randomly chosen subjects with low sEpoR
(#62.5 pg/ml) were included for this substudy. Data are depicted
as mean IL-6 levels in pg/ml +/2 S.E.M for both groups.
Results
sEpoR Is Present in the Serum of Dialysis Patients
We initially attempted to characterize sEpoR in uremic serum
using two different antibodies by western blot and were unable to
detect any specific band that was consistent with the expected size
of sEpoR. However, immunoprecipitation with goat anti-human
Erythropoietin and Anemia
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anti-human erythropoietin receptor revealed a clear band of
approximately 27 kDa consistent with the expected size of sEpoR
in 6 representative dialysis patient samples (Figure 1a). A band of
similar size was also detected when immunoprecipitation and
western blotting was performed with the same antibodies in
reverse order (Figure 1b). Purification of the 27 kDA protein
from sera of uremic subjects and analysis by mass spectrometry
revealed at least 2 different peptides (GPEELLCFTERL and
YEVDVSAGNGAGSVQR) corresponding to the N-terminal
extracellular region of the EpoR. Taken together with the
immunoprecipation studies (Figure 1a, 1b), these data suggest
that dialysis subjects have sEpoR in their serum.
Elevated sEpoR Levels at Initiation of Dialysis Predict
Subsequent Erythropoietin Dose
We measured sEpoR levels by ELISA in representative group of
697 incident dialysis patients. The distribution of sEpoR levels is
shown in Figure 2a. Most of the patients had low levels of sEpoR
(less than or equal to 100 pg/ml). However, a subset of patients
demonstrated significantly elevated values. The distribution plot
suggested that approximately 5–6% of end-stage renal disease
(ESRD) subjects had high circulating levels of EpoR (.2 standard
deviations from the mean), and the subjects were divided
accordingly The mean levels of sEpoR at the initiation of chronic
hemodialysis were 243761299 pg/ml in the High group (n=36)
and 1126111 pg/ml in the Low group (n=661) (p,0.001).
Median values were 2147 pg/ml (inter-guartile range 1400–3445)
and 69 pg/ml (inter-quartile range 62.5–101), respectively.
Table 1 shows the baseline characteristics of the Low and High
sEpoR groups. We found no difference between the two groups
with respect to age, race, gender, body mass index (BMI), or blood
pressure. Importantly ferritin, iron saturation and hemoglobin
were not different. In addition correlations between baseline
sEpoR and ferritin, iron saturation, and hemoglobin levels were
also not significant (p.0.05). Erythropoietin resistance has been
associated with osteodystrophy and elevated parathyroid hormone
(PTH) [9,10], but PTH was also not different between the groups,
and the correlation with PTH in the entire group was not
significant as well (r=20.03, p=0.33). Bone biopsies were not
available for these subjects to confirm osteodystrophy. Hyperten-
sion as an etiology of ESRD was slightly over represented in the
Low sEpoR group. Nevertheless, standard clinical parameters did
not appear to be associated with sEpoR levels.
To determine if sEpoR levels at the initiation of chronic dialysis
are associated with subsequent erythropoietin dose, we compared
longitudinal weekly erythropoietin administration in our Low and
High sEpoR groups (Figure 2b). Erythropoietin administration
not only differed with time (P,0.001), but also according to
sEpoR status by 90 and most notably by 180 days following
hemodialysis initiation (P=0.038). We next examined respective
mean hemoglobin levels over the same time period because
erythropoietin resistance has been associated with increasing
erythropoietin administration in the face of lower hemoglobin
levels [42]. By day 180, the Low sEpoR group had slightly higher
hemoglobin levels despite receiving lower weekly erythropoietin
doses (Figure 2c). Next, rather than categorize the cohort
according to baseline sEpoR levels, we examined the cumulative
erythropoietin administration as measure of erythropoietin
resistance suggested by previous investigators [43]. The mean
cumulative erythropoietin administration over 180 days following
hemodialysis initiation was 542,1026330,308 IU. We categorized
the entire cohort into quintiles of cumulative erythropoietin
administration and within each quintile examined the mean
baseline sEpoR levels (Figure 2d). Those that received higher
cumulative erythropoietin doses over the study period had
progressively higher baseline sEpoR levels. We then performed
logistic regression analyses to determine the independent baseline
variables associated with the highest cumulative erythropoietin
administration (Quintile 5). In addition to High vs. Low sEpoR
levels, we adjusted for characteristics previously linked with
erythropoietin administration including age, race, sex, cause of
end-stage renal failure (diabetes, hypertension, glomerulonephritis,
other), and baseline exposures such as arterio-venous access
(fistula, graft, catheter), weight, serum ferritin, transferrin satura-
tion, and PTH levels [42–44]. The risk for requiring the highest
Figure 1. sEpoR characterization in uremic serum. 1a. Soluble EpoR is detectable in serum from dialysis patients by western blot. Human
serum was subjected to immunoprecipitation with goat anti-human erythropoietin receptor antibody (R&D Systems, AF-322-PB) followed by western
blotting with mouse monoclonal anti-human erythropoietin receptor (R&D Systems, MAB307). Both antibodies recognize the extracellular domain of
the receptor. Lanes 1–6 are serum from 6 representative dialysis patients, lane 7 is blank and lane 8 is recombinant sEpoR (Sigma Aldrich E0643, Saint
Louis MI). Shown in the serum samples is a band of expected molecular weight of approximately 27 kDa. The control sEpoR with Fc tag is consistent
with the manufacturers reported molecular weight of 32 kDa. 1b. Soluble EpoR is also detected using the same dialysis patient serum samples by
performing immunoprecipitation in reverse order. In this experiment immunoprecipitation was done with mouse monoclonal anti-human
erythropoietin receptor (R&D Systems, MAB307) followed by western blotting with goat anti-human erythropoietin receptor (R&D Systems, AF-322-
PB). Lanes 1 to 3 are serum from 3 dialysis patients, and lane 4 is recombinant sEpoR-Fc (Sigma, 307) as positive control.
doi:10.1371/journal.pone.0009246.g001
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was approximately 3-fold higher (OR 2.8, 95% CI 1.3–6.4).
sEpoR Blocks EPO Mediated Signaling In Vitro
We next sought to test the hypothesis that circulating sEpoR
may block erythropoietin mediated signaling via the membrane
bound receptor in vitro. We selected the BaF3/EPOR cell line
which is a murine pro B cell line stably transfected with EPOR.
This cell line is well characterized and responds to erythropoietin
by increasing intracellular signaling via the Stat-5 and Janus kinase
2 (Jak2) pathways resulting in cell proliferation [35,36,45,46].
Using the BaF3/EpoR cells we established an in vitro system in
which to test Stat-5 phosphorylation in response to erythropoietin.
Figure 3a is a dose-response curve demonstrating increased Stat-
5 phosphorylation in response to increasing erythropoietin.
Figure 3b shows that addition of recombinant sEpoR blocks
erythropoietin mediated Stat-5 phosphorylation in this system at
concentrations ranging from 50 ng/mL to 5,000 ng/mL. Quan-
tification of this inhibition is shown in Figure 3c as the ratio of
phospho-Stat-5 to total Stat-5.
We next tested whether serum from patients with high levels of
sEpoR blocks erythropoietin mediated signaling when compared
Figure 2. Relationship of sEpoR and erythropoietin dosage in human ESRD subjects. 2a. This figure shows the distribution of sEpoR levels
as measured by ELISA in our sample of 697 dialysis patients. 2b. Erythropoietin dose over time for the Low and High sEpoR groups. Erythropoietin
dose at the start of dialysis (Days 0 to14) was the same in both groups, 17,908 IU/week in the High sEpoR group vs. 18,851 IU/week in the Low sEpoR
group. Between days 14 and 90 the High group received 27,819 IU/week vs. 25,906 IU/week in the Low group. By days 90 and 180 the High sEpoR
group required a significantly greater dose of erythropoietin then the Low sEpoR group (26,977 IU/week vs. 20,173 IU/week, p=0.038). It is notable
that the average dose rose in both groups over the period 14 to 90 days but then fell again over the 90 to 180 day period as might be expected in
patients starting erythropoietin therapy. 2c. Mean hemoglobin was compared for the Low and High sEpoR groups at three time points (Days 0 to14,
14 to 90 and 90 to 180). Hemoglobin at the start of dialysis (Days 0-14) was not statistically different between the High and Low sEpoR groups (10.5
vs. 10.3 mg %). Between 90 and 180 day there was a trend toward lower hemoglobin in the High sEpoR group 12.4 vs. 11.9 that approached
statistical significance (p=0.054). This suggests that even though both groups likely had identical hemoglobin targets, the high sEpoR group may
have impaired erythropoietin response even with significantly higher erythropoietin dose. 2d. The cohort was divided according to quintiles of
cumulative EPO dose during the study period, and within each quintile examined the mean sEpoR level. The mean sEpoR values according to quintile
were: Quintile 1: 220644 pg/ml; Quintile 2: 213647 pg/ml; Quintile 3: 181628 pg/ml; Quintile 4: 242661 pg/ml; Quintile 5: 304667 pg/ml, p value
for trend =0.038. The mean cumulative Epo doses in units according to quintile were: Quintile 1: 209,00464863, Quintile 2: 347,01962655, Quintile
3: 459,71963362, Quintile 4: 622,46065334, Quintile 5: 1,077,666625,576.
doi:10.1371/journal.pone.0009246.g002
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BaF3/EpoR were stimulated with 50 mU/ml erythropoietin in
the presence and absence of 10% human serum from patients with
high and low levels of sEpoR. Figure 3d shows a representative
western blot from this experiment. Quantification by densitometry
(Figure 3e) shows a significant (p,0.05) decrease in Stat-5
phosphorylation when BaF3/EpoR cells were exposed to serum
from patients with high (.4000 pg/ml) sEpoR as compared to
serum from patients with sEpoR levels #62.5 pg/ml).
sEpoR Is Increased by Pro-Inflammatory Cytokines IL-6
and TNF-a
The source of circulating sEpoR is also unknown. It is plausible
that sEpoR levels are regulated, and that sEpoR has physiologic
function in some tissues. Some have noted a positive correlation
between sEpoR levels and the degree of erythropoiesis [25] while
others have not observed an association [28]. In addition, recent
data shows a correlation between elevated TNF-a, IL-6 and IL-8
levels and anemia in patients with chronic kidney disease [47]. We
hypothesized that sEpoR may be stimulated by inflammatory
cytokines present in the uremic patients. In order to test this
hypothesis we selected K562 cells a cell line known to express
EpoR [48,49]. We used phorbol ester (PMA) as a positive control
as it has been shown to induce secretion of soluble growth factor
receptors in other cell lines [50]. We found that sEpoR in the cell
supernatant was increased significantly over baseline by exposure
to PMA, IL-6 and TNF-a but not IL-8 (Figure 4a). We then
measured circulating levels of IL-6 in a subset of patients with high
sEpoR and low sEpoR and found that IL-6 levels were on average
2.5 times higher in subjects with high circulating levels of sEpoR
than in subjects with low sEpoR levels (Figure 4b).
Discussion
In this study we demonstrate that sEpoR is present in the serum
of patients at the initiation of CHD, and that higher levels at the
start of dialysis are independently associated with subsequent
erythropoietin dose administered in the ensuing 6 months from
start of treatment. We also demonstrate that sEpoR is a functional
protein and inhibits erythropoietin mediated Stat-5 phosphoryla-
tion. We further show that serum with high levels of sEpoR
decreases erythropoietin mediated Stat-5 phosphorylation com-
pared with serum from patients with low sEpoR levels suggesting
that sEpoR may compete with membrane bound EPOR and
inhibit erythropoietin stimulated erythropoiesis. Additionally, we
suggest a mechanism for elevated sEpoR by showing that IL-6 and
TNF-a can increase sEpoR production in the supernatant of cell
lines expressing endogenous EpoR. Importantly, we also demon-
strate that subjects with high sEpoR on average had higher
circulating levels of IL-6 than subjects with low sEpoR.
The hypothesis that sEpoR may modulate erythropoietin
signaling has biologic plausibility for several reasons. First, other
investigators have shown that sEpoR may block EpoR signaling in
vitro [25,51]. Second there is recent data to suggest that sEpoR
may inhibit erythropoietin signaling in vivo. Soluble EpoR is
expressed in the brain and is down-regulated in response to
chronic hypoxia in a recently described murine model [30]. This
down-regulation contributes to increased minute ventilation.
Infusion of exogenous sEpoR decreases endogenous erythropoietin
signaling and blocks the increase in minute ventilation [30]. Also,
transgenic expression of sEpoR can block erythropoietin in a rat
model [52]. Furthermore, many cytokines of the superfamily type
1 transmembrane proteins (of which EpoR is a member) are
synthesized in soluble forms, and alter native ligand receptor
binding [26,27,53]. Two other groups have reported sEpoR levels
in patients with chronic kidney disease or on dialysis but they were
not able to show a physiologic role for this protein [25,26]. Here
we confirm the presence of sEpoR by immunoprecipitation and
ELISA of serum and show that serum enriched in sEpoR inhibits
erythropoietin mediated Stat-5 phosphorylation suggesting that
sEpoR may have a physiologic role rather than being an
epiphenomenon related to the degree of erythropoiesis.
We speculated that sEpoR levels may be modulated by
cytokines present in the chronic inflammatory state present in
many dialysis patients. Data regarding the regulation of sEpoR is
limited, although membrane bound EpoR is known to be
regulated by several cytokines such as TNF-a, IL-1b, and IL-6
[54,55]. Hypoxia and erythropoietin may also stimulate EpoR
expression. EpoR is regulated by hypoxia-inducible factor 1 [56]
and recent data shows increased EpoR expression in primary
human venous endothelial cells and bone marrow vascular
endothelial cells under hypoxic conditions and in response to
erythropoietin [57]. It is unknown if sEpoR is produced in
proportion to EpoR of if it is independently regulated. Lysosomal
degradation plays an important role in altering the cell surface
expression of many cytokine receptors [58]. Interestingly, blocking
Table 1.
sEpoR Low sEpoR High p-value
N 661 36
Age (Years) 67613 68615 0.76
Female (%) 51 36 0.09
Race (%) 0.30
White 63 72
Black 33 28
Other 4 0
aBMI (kg/m2) 26662 7 67 0.66
Etiology of renal failure (%) 0.03
Diabetes Mellitus 47 47
Hypertension 37 22
Glomerulonephritis 8 8
Polycystic Kidney Disease 2 8
Other 6 15
Vascular Access 0.76
Fistula 22 20
Graft 13 17
Catheter 65 63
Systolic blood pressure (mmHg) 144622 140618 0.81
Diastolic blood pressure (mmHg) 72613 71610 0.31
bPTH (bio-intact; pg/ml) 2976302 2786268 0.81
Calcium (mg/dl) 8.560.7 8.760.6 0.31
Phosphorus (mg/dl) 4.561.5 4.361.8 0.46
Ferritin (ng/ml) 2976512 3186273 0.25
Iron saturation (%) 20610 1868 0.25
White blood cell count (cells/ml) 8638 63 0.69
Platelets (cells/dl) 239694 211681 0.81
Results are expressed as mean 6 standard deviation.
aBMI–body mass index.
bPTH–parathyroid hormone.
doi:10.1371/journal.pone.0009246.t001
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sEpoR by 2 to 5 fold but only increased membrane bound EpoR
1.5 fold arguing for differential regulation of the two proteins [59].
Here we provide evidence that IL-6 and TNF-a can increase
sEpoR in the supernatant of cells known to express the native
receptor and that subjects with high sEpoR on average had higher
circulating levels of IL-6. This suggests one possible mechanistic
link between inflammation and erythropoietin resistance.
Our preliminary data suggest that elevated sEpoR levels at
initiation of CHD identify those that require higher erythropoietin
doses over the ensuing 6 months. Importantly, sEpoR levels were
not correlated with other parameters considered linked to
erythropoietin resistance such as ferritin, iron saturation, and
parathyroid hormone levels. Higher erythropoietin doses were
received in the context of achieving lower hemoglobin values
compared to those with lower sEpoR levels. It is interesting to find
that mean weekly erythropoietin doses differed most markedly
between days 90 and 180. This may be because starting doses of
erythropoietin are usually similar when patients initiate CHD (as
seen in Figure 2b) given the low hemoglobin levels at the
initiation of hemodialysis and the ease of administration of
standard doses in busy dialysis units. In this context, it is likely that
only later is erythropoietin resistance (even in a subtle form)
uncovered. Furthermore, since the half-life of red blood cells is 120
days, it is likely that the effects of sEpoR are more prominent at
180 days rather than at 90 days. There are recent data showing
that higher erythropoietin dose is associated with increased
mortality, and a subset of patients require significantly higher
amounts of erythropoietin to sustain adequate hemoglobin levels
[60]. It is not clear if this is related to erythropoietin itself, or is
associated with risk factors such as chronic inflammation. For this
study we chose to closely examine the link between sEpoR levels
and subsequent erythropoietin dose, hence we required all subjects
to remain alive during the study period. Future studies should
examine whether there may be a link between sEpoR levels and
outcomes including death.
In this initial description sEpoR levels independently identified
those that required higher doses of erythropoietin in the ensuing 6
months even after accounting for standard baseline clinical
characteristics and laboratory measures. In these analyses we
Figure 3. Functional characterization of sEpoR. 3a. Western blot showing increasedphospho-Stat-5 in the presence of increasing
erythropoietin (25 to 5000 mU/ml) in BaF3/EpoR cell lysates. 3b. Representative western blot showing total phospho-Stat-5 and Stat-5 in the
presence of erythropoietin 5000 mU/ml and varying concentrations of recombinant sEpoR-Fc (50 -5000 ng/ml). Phospho-Stat-5 decreases with
increasing recombinant sEpoR. 3c. Quantification of sEpoR-Fc inhibition of phospho-Stat 5 (Figure 3b). Ratios of phospho/total Stat-5 (mean 6 SD,
n=3) represented as a percentage of control (Epo alone). *represents p,0.05. 3d. Serum from patients with high sEpoR blocks erythropoietin
mediated Stat-5 phosphorylation. Shown is the ratio of phospho-Stat-5 to Stat-5 as measured by densitometry. Serum starved BaF3/EpoR cells were
exposed to vehicle (negative control), erythropoietin at 50 mU/ml (positive control) and erythropoietin plus 10% serum with Low sEpoR (#62.5 pg/ml)
or serum with high sEpoR ($4000 pg/ml) for 10 minutes. Cells were lysed in RIPA buffer and 10 ug protein/lane was run on a 4-12% denaturing gel.
Gels were transferred and blotted with anti-Stat-5 and anti-phospho-Stat 5. 3e. Quantification of western data (Figure 3d). Ratios of phospho/total
Stat-5 (mean 6 SD, n=5 individual patient samples each for low sEpoR and high sEpoR) represented as a percentage of control (Epo alone).
*represents p,0.05.
doi:10.1371/journal.pone.0009246.g003
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erythropoietin resistance, including PTH, iron status, and
measures of inflammation such as ferritin. However, we did not
measure novel circulating markers associated with erythropoietin
resistance such as pro-hepcidin which may be a marker for
inflammation and alter iron availability [13–15], soluble transfer-
rin receptor which has been shown to be decreased in chronic
kidney disease [16–19], and C-reactive protein (CRP). Patients
with elevated CRP require higher erythropoietin dose and there
may be decreased clearance of inflammatory cytokines such as
TNF-a, IL-1 and IL-6 [9,61]. At high levels these cytokines can
blunt erythropoietin action on bone marrow precursor cells [10].
It is also possible that some inflammatory cytokines may regulate
sEpoR production themselves or they may both be associated with
a common factor. Our in vitro data suggests that IL-6 and TNF-a
may directly stimulate sEpoR production. In future work it would
be reasonable to measure pro-hepcidin, soluble transferrin
receptor, CRP, IL-6 and TNF-a to see if any of these factors
are associated with sEpoR levels.
We studied subjects representative of incident US dialysis
patients. However, erythropoietin dosing varies significantly by
country with most studies showing the highest doses in the United
States [62]. A recent review of erythropoietin dosing patterns in 12
countries showed that average weekly erythropoietin dose among
chronic stable dialysis patients in the US was highest at 17,360 IU
per week compared with a low of 5,297 per week in Japan [63]. In
this study greater erythropoietin dose was associated with greater
mean hemoglobin concentration. Our findings would need to be
validated in other patient populations, including European and
Asian groups to assess generalizability. Our data may have
particular relevance to cancer subjects as several tumor cell lines
have been shown to secret sEpoR [26] and in whom higher doses
of erythropoietin have been associated with mortality [64].
The data presented showing increased sEpoR in response to IL-
6 and TNF-a is preliminary. Future work includes a full analysis of
sEpoR in response to these and other potential inflammatory
cytokines. Questions to be answered include what is the effect on
membrane bound EpoR, what is the time course for sEpoR
release, and is sEpoR regulated at a translational, transcriptional,
or post-transcriptional level? Importantly, we also do not know
whether sEpoR may also be involved in the pathogenesis of
anemia of chronic disease, which is also thought to be secondary to
chronic inflammation [65].
In summary, our findings suggest that sEpoR may play a role in
the response of dialysis patients to exogenous erythropoietin and
sEpoR may be produced in response to inflammatory cytokines. A
better understanding of sEpoR regulation and it association with
other factors known to contribute to erythropoietin resistance may
lead to more strategic and effective erythropoietin dosing
protocols. If sEpoR can be shown in further studies to inhibit
erythropoietin effectiveness in dialysis patients then therapeutic
strategies aimed at decreasing sEpoR may be useful.
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